Biotech IV Monitor

TERN — Terns Pharmaceuticals Inc.

Acquired by Merck & Co. · May 2026
Terns Pharmaceuticals Inc. was acquired by Merck & Co. in May 2026. TERN no longer trades, so its trials are no longer stock catalysts and are left off the trial calendar. The records below are kept for reference; the programs now belong to Merck & Co., and their dates may not have been updated since.

Clinical trial readout dates for Terns Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is November 2029.

Next readoutNovember 2029in ~36 months
Upcoming readouts1none in Phase 3

Upcoming readouts

Phase 1/2 MK-4208
Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Chronic Myeloid Leukemia, Chronic Phase · NCT06163430
November 2029
Recruiting

Companies working on similar indications

Discussion

No messages yet. If you follow TERN, you can start the conversation.
Contact — questions or corrections about TERN: dukeupt@gmail.com